Literature DB >> 18090422

Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia.

William T Hu1, Joseph E Parisi, David S Knopman, Bradley F Boeve, Dennis W Dickson, J Eric Ahlskog, Ronald C Petersen, Keith A Josephs.   

Abstract

We compared the clinical characteristics of 3 repeat (3R) and 4 repeat (4R) tau-positive cases (tauopathies) presenting as behavior variant frontotemporal dementia (bv-FTD). We identified and retrospectively reviewed demographics and clinical features of patients with pathologically confirmed tau-positive frontotemporal lobar degeneration in a blinded fashion. Those presenting as bv-FTD were divided according to their tau isoform, 3R versus 4R, and compared with age-matched and sex-matched control patients with 4R tauopathies but presenting clinical syndromes other than bv-FTD. Twenty-four cases with tau-positive bv-FTD and 18 4R tau-positive controls were included in the study. Patients with 4R tauopathies had significantly shorter disease duration than patients with 3R tauopathy (median, 6.5 y vs. 9.5 y; P<0.05), despite similar age of disease onset and regardless of whether bv-FTD was the presenting clinical syndrome. Among bv-FTD cases, those with 4R tauopathies were more likely to display behavioral underactivity than those with 3R tauopathy (P=0.03), although 3R and 4R tauopathy patients shared many similar clinical features. In summary, survival in 4R tauopathies seemed independent of the presenting clinical phenotype, and there may be subtle clinical differences between bv-FTD patients with 3R and 4R tauopathies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18090422     DOI: 10.1097/WAD.0b013e31815bf5e5

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  10 in total

1.  Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia.

Authors:  Christopher Kobylecki; Matthew Jones; Jennifer C Thompson; Anna M Richardson; David Neary; David M A Mann; Julie S Snowden; Alexander Gerhard
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

Review 2.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

3.  Extraction and Analysis of Risk Elements for Korean Homecare Patients with Senile Dementia.

Authors:  Mi-Hyun Choi; Hyung-Sik Kim; BoSeong Kim; Jung-Chul Lee; Sung-Jun Park; Ul-Ho Jeong; Ji-Hye Baek; Hyun-Jun Kim; Dae-Woon Lim; Soon-Cheol Chung
Journal:  J Behav Health Serv Res       Date:  2016-01       Impact factor: 1.505

Review 4.  Behavioural variant frontotemporal dementia--defining genetic and pathological subtypes.

Authors:  Jonathan D Rohrer
Journal:  J Mol Neurosci       Date:  2011-05-11       Impact factor: 3.444

5.  Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia.

Authors:  David J Irwin; Corey T McMillan; EunRan Suh; John Powers; Katya Rascovsky; Elisabeth M Wood; Jon B Toledo; Steven E Arnold; Virginia M-Y Lee; Vivianna M Van Deerlin; John Q Trojanowski; Murray Grossman
Journal:  Neurology       Date:  2014-07-03       Impact factor: 9.910

6.  Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study.

Authors:  Jennifer L Whitwell; Scott A Przybelski; Stephen D Weigand; Robert J Ivnik; Prashanthi Vemuri; Jeffrey L Gunter; Matthew L Senjem; Maria M Shiung; Bradley F Boeve; David S Knopman; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Keith A Josephs
Journal:  Brain       Date:  2009-09-17       Impact factor: 13.501

Review 7.  Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders.

Authors:  Aurélie de Rus Jacquet; Hélèna L Denis; Francesca Cicchetti; Melanie Alpaugh
Journal:  Mol Psychiatry       Date:  2021-01-25       Impact factor: 13.437

8.  Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant.

Authors:  Helen Ling; H Ling; R de Silva; L A Massey; R Courtney; G Hondhamuni; N Bajaj; J Lowe; J L Holton; A Lees; T Revesz
Journal:  Neuropathol Appl Neurobiol       Date:  2014-02       Impact factor: 8.090

9.  Astrocyte senescence may drive alterations in GFAPα, CDKN2A p14ARF, and TAU3 transcript expression and contribute to cognitive decline.

Authors:  Jed J Lye; Eva Latorre; Ben P Lee; Stefania Bandinelli; Janet E Holley; Nicholas J Gutowski; Luigi Ferrucci; Lorna W Harries
Journal:  Geroscience       Date:  2019-10-25       Impact factor: 7.713

10.  Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.

Authors:  Marwa Malhis; Senthilvelrajan Kaniyappan; Isabelle Aillaud; Ram Reddy Chandupatla; Lisa Marie Ramirez; Markus Zweckstetter; Anselm H C Horn; Eckhard Mandelkow; Heinrich Sticht; Susanne Aileen Funke
Journal:  Chembiochem       Date:  2021-09-12       Impact factor: 3.164

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.